JZJ Chain Drugstore - Public Comps and Valuation Multiples

JZJ Chain Drugstore Overview

About JZJ Chain Drugstore

JZJ Chain Drugstore Corp is engaged in the retail chain business of health products such as medicines, health foods, personal care products, household health products, convenience foods, and daily consumables and provides related professional services.

Founded

2004

HQ

Employees

n/a

Website

jzj.cn

Sectors

Pharmacies

Financials

Last FY Revenue $1.3B

Last FY EBITDA $159M

EV

$997M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

JZJ Chain Drugstore Financials

See JZJ Chain Drugstore valuation multiples based on analyst estimates

JZJ Chain Drugstore P&L

In the most recent fiscal year, JZJ Chain Drugstore reported revenue of $1.3B and EBITDA of $159M.

JZJ Chain Drugstore expects next 12-month revenue of XXX and NTM EBITDA of XXX

See JZJ Chain Drugstore valuation multiples based on analyst estimates

	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	XXX	$1.3B	XXX	XXX	XXX
Gross Profit	XXX	$466M	XXX	XXX	XXX
Gross Margin	XXX	36%	XXX	XXX	XXX
EBITDA	XXX	$159M	XXX	XXX	XXX
EBITDA Margin	XXX	12%	XXX	XXX	XXX
EBIT	XXX	$51.1M	XXX	XXX	XXX
EBIT Margin	XXX	4%	XXX	XXX	XXX
Net Profit	XXX	$18.0M	XXX	XXX	XXX
Net Margin	XXX	1%	XXX	XXX	XXX
Net Debt	XXX	$283M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for JZJ Chain Drugstore including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, JZJ Chain Drugstore achieved $1.3B in revenue and $159M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	Analyst estimates available to subscribers	$1.3B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$466M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	35.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$159M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	12.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$51.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	3.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$18.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	1.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	$283M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for JZJ Chain Drugstore

This financial data table provides comprehensive performance metrics for JZJ Chain Drugstore, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, JZJ Chain Drugstore reported $1.3B in total revenue.
Fiscal year EBITDA was $159M.
The company maintained a gross profit margin of 35.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 12.2%.
Net profit margin reached 1.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for JZJ Chain Drugstore. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

JZJ Chain Drugstore Stock Performance

JZJ Chain Drugstore has current market cap of CNY 3.4B (or $473M), and EV of CNY 7.1B (or $997M).

Market Cap Evolution

JZJ Chain Drugstore Stock Data

As of September 15, 2025, JZJ Chain Drugstore's stock price is CNY 22 (or $3).

See JZJ Chain Drugstore trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$997M	$473M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

JZJ Chain Drugstore Valuation Multiples

JZJ Chain Drugstore's trades at 0.8x EV/Revenue multiple, and 6.3x EV/EBITDA.

See valuation multiples for JZJ Chain Drugstore and 15K+ public comps

JZJ Chain Drugstore Financial Valuation Multiples

As of September 15, 2025, JZJ Chain Drugstore has market cap of $473M and EV of $997M.

Equity research analysts estimate JZJ Chain Drugstore's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

JZJ Chain Drugstore's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$473M	XXX	$473M	XXX	XXX	XXX
EV (current)	$997M	XXX	$997M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	0.8x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	6.3x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	19.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	26.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	29.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get JZJ Chain Drugstore Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

JZJ Chain Drugstore Margins & Growth Rates

JZJ Chain Drugstore's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

JZJ Chain Drugstore's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

JZJ Chain Drugstore's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for JZJ Chain Drugstore and other 15K+ public comps

JZJ Chain Drugstore Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	12%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	15%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	32%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial